$3.29 Million in Sales Expected for Viveve Medical, Inc. (VIVE) This Quarter
Wall Street brokerages expect Viveve Medical, Inc. (NASDAQ:VIVE) to report sales of $3.29 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Viveve Medical’s earnings, with the lowest sales estimate coming in at $3.13 million and the highest estimate coming in at $3.57 million. Viveve Medical posted sales of $1.56 million during the same quarter last year, which would indicate a positive year over year growth rate of 110.9%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 10th.
On average, analysts expect that Viveve Medical will report full-year sales of $3.29 million for the current fiscal year, with estimates ranging from $14.82 million to $16.00 million. For the next financial year, analysts anticipate that the firm will report sales of $25.00 million per share, with estimates ranging from $21.36 million to $28.20 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.06. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $2.70 million. Viveve Medical had a negative net margin of 255.11% and a negative return on equity of 232.94%.
Several analysts have commented on VIVE shares. B. Riley reaffirmed a “buy” rating and set a $10.00 price objective on shares of Viveve Medical in a research note on Wednesday, May 17th. ValuEngine raised Viveve Medical from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Raymond James Financial, Inc. started coverage on Viveve Medical in a research note on Thursday, May 25th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, Cowen and Company started coverage on Viveve Medical in a research note on Wednesday, May 3rd. They set an “outperform” rating and a $11.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.25.
A number of hedge funds have recently bought and sold shares of the stock. EcoR1 Capital LLC bought a new stake in Viveve Medical during the first quarter valued at approximately $1,583,000. Granahan Investment Management Inc. MA boosted its position in Viveve Medical by 8.0% in the first quarter. Granahan Investment Management Inc. MA now owns 396,494 shares of the company’s stock valued at $2,510,000 after buying an additional 29,364 shares during the last quarter. Wexford Capital LP boosted its position in Viveve Medical by 23.9% in the first quarter. Wexford Capital LP now owns 777,124 shares of the company’s stock valued at $4,919,000 after buying an additional 150,000 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Viveve Medical during the first quarter valued at about $5,942,000. Finally, HighTower Advisors LLC boosted its position in Viveve Medical by 36.9% in the first quarter. HighTower Advisors LLC now owns 1,293,718 shares of the company’s stock valued at $8,192,000 after buying an additional 348,682 shares during the last quarter. 60.85% of the stock is owned by hedge funds and other institutional investors.
Viveve Medical (NASDAQ VIVE) opened at 7.30 on Friday. The stock has a 50 day moving average price of $7.57 and a 200-day moving average price of $6.07. Viveve Medical has a one year low of $3.75 and a one year high of $11.16. The firm’s market capitalization is $141.28 million.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.